BMJ Open Epidemic potential of *Escherichia coli* ST131 and *Klebsiella pneumoniae* ST258: a systematic review and meta-analysis

M J D Dautzenberg,^{1,2} M R Haverkate,¹ M J M Bonten,^{1,2} M C J Bootsma^{1,3}

To cite: Dautzenberg MJD, Haverkate MR, Bonten MJM, et al. Epidemic potential of *Escherichia coli* ST131 and *Klebsiella pneumoniae* ST258: a systematic review and meta-analysis. *BMJ Open* 2016;**6**:e009971. doi:10.1136/bmjopen-2015-009971

► Prepublication history and additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjopen-2015-009971>).

MJDD and MRH contributed equally.

Received 16 September 2015
Revised 15 December 2015
Accepted 15 January 2016

CrossMark

¹Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands

²Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands

³Faculty of Sciences, Department of Mathematics, Utrecht University, Utrecht, The Netherlands

Correspondence to

MR Haverkate;
m.r.haverkate-2@umcutrecht.nl

ABSTRACT

Objectives: Observational studies have suggested that *Escherichia coli* sequence type (ST) 131 and *Klebsiella pneumoniae* ST258 have hyperendemic properties. This would be obvious from continuously high incidence and/or prevalence of carriage or infection with these bacteria in specific patient populations. Hyperendemicity could result from increased transmissibility, longer duration of infectiousness, and/or higher pathogenic potential as compared with other lineages of the same species. The aim of our research is to quantitatively estimate these critical parameters for *E. coli* ST131 and *K. pneumoniae* ST258, in order to investigate whether *E. coli* ST131 and *K. pneumoniae* ST258 are truly hyperendemic clones.

Primary outcome measures: A systematic literature search was performed to assess the evidence of transmissibility, duration of infectiousness, and pathogenicity for *E. coli* ST131 and *K. pneumoniae* ST258. Meta-regression was performed to quantify these characteristics.

Results: The systematic literature search yielded 639 articles, of which 19 data sources provided information on transmissibility (*E. coli* ST131 n=9; *K. pneumoniae* ST258 n=10), 2 on duration of infectiousness (*E. coli* ST131 n=2), and 324 on pathogenicity (*E. coli* ST131 n=285; *K. pneumoniae* ST258 n=39). Available data on duration of carriage and on transmissibility were insufficient for quantitative assessment. In multivariable meta-regression *E. coli* isolates causing infection were associated with ST131, compared to isolates only causing colonisation, suggesting that *E. coli* ST131 can be considered more pathogenic than non-ST131 isolates. Date of isolation, location and resistance mechanism also influenced the prevalence of ST131. *E. coli* ST131 was 3.2 (95% CI 2.0 to 5.0) times more pathogenic than non-ST131. For *K. pneumoniae* ST258 there were not enough data for meta-regression assessing the influence of colonisation versus infection on ST258 prevalence.

Conclusions: With the currently available data, it cannot be confirmed nor rejected, that *E. coli* ST131 or *K. pneumoniae* ST258 are hyperendemic clones.

INTRODUCTION

Infections caused by *Escherichia coli* and *Klebsiella pneumoniae* producing extended-

Strengths and limitations of this study

- A comprehensive literature search combined with meta-regression analyses was performed to quantify evidence of hyperendemicity of *Escherichia coli* ST131 and *Klebsiella pneumoniae* ST258 focusing on transmissibility, durations of infectiousness and pathogenicity.
- There is a large heterogeneity in reported prevalences and a limited amount of data available on transmissibility and duration of infectiousness.
- With the currently available data, it can neither be confirmed nor rejected, that *E. coli* ST131 or *K. pneumoniae* ST258 are hyperendemic clones.

spectrum β -lactamases (ESBL) or carbapenemases, are increasing worldwide. There is growing evidence that certain clonal lineages of these species, such as *E. coli* sequence type (ST) 131 and *K. pneumoniae* ST258, have more epidemic potential than other lineages within their species group. *E. coli* ST131 was first described in 2008¹ and *K. pneumoniae* ST258 in 2009.² *E. coli* ST131 is reported from around the globe, both in healthcare settings and in the community,^{3–4} and is mostly associated with ESBL production and fluoroquinolone resistance.^{3–5} *K. pneumoniae* ST258 is mainly associated with *K. pneumoniae* carbapenemase (KPC) production, and other resistance mechanisms,⁶ and is widespread in the USA, and expanding in Europe.^{6–8} In the scientific literature, *E. coli* ST131 and *K. pneumoniae* ST258 are widely considered hyperendemic clones.^{3–5–6–8–9} But the evidence underlying these assumptions is not that obvious.^{3–5} If *E. coli* ST131 or *K. pneumoniae* ST258 are truly hyperendemic clones, interventions may be targeted to these specific clones.

From a simple model in which patients can be susceptible, colonised or infected (figure 1), the characteristics of hyperendemicity follow as explained below. Susceptible hosts can acquire colonisation through

Figure 1 Simple model.

transmission, either directly (from another colonised or infected person) or indirectly (from the environment or via the hands of healthcare workers). Both colonised and infected patients contribute to transmission, as long as they are infectious, which can be expressed with the duration of colonisation. Duration of colonisation can be influenced by fitness cost associated with resistance or by antibiotic use. Colonisation can proceed to infection, which typically occurs in a fraction of colonised patients,¹⁰ and the rate of this progression can be expressed as the pathogenicity level. Decolonisation can occur in both colonised and infected persons.

To be hyperendemic, a clone has to have advantages over other clones in at least one of the traits: transmissibility, duration of colonisation or pathogenicity. Therefore, we define a hyperendemic clone as ‘a clone that is more transmissible, has a longer duration of colonisation, and/or is more pathogenic than other clones of the same species’. The presence of any or more of these traits will then lead to a continuously high incidence and/or prevalence of carriage or disease in a specific patient population. We performed a systematic review to quantitatively estimate these critical parameters for *E. coli* ST131 and *K. pneumoniae* ST258, in order to investigate whether *E. coli* ST131 and *K. pneumoniae* ST258 are truly hyperendemic clones.

METHODS

Search strategy

A PubMed and EMBASE search was performed to retrieve relevant articles published until 1 January 2015. The complete search string can be found in online supplementary text 1. A cross-reference check was performed to include relevant articles not found during the search. Only English, full-text articles were included. Articles unavailable online were requested from the authors. The Meta-analysis Of Observational Studies in Epidemiology statement¹¹ was followed for reporting in this paper.

Study selection

Titles and abstracts were independently reviewed by two reviewers (MRH and MJDD) and selected for further review if they met the inclusion criteria. Selections were compared between the two reviewers, and if consensus was not reached, a third reviewer (MCJB or MJMB) was consulted.

The inclusion criteria for articles on transmissibility were that possible transmissions should be described, and the number of cases should be reported. Outbreak reports were included. Articles focusing on duration of colonisation should include at least two cultures per patient taken at two different time points. Pathogenicity was defined as the difference in the prevalence of ST131 or ST258 in infections (clinical isolates) compared to colonisation. We considered a clone to be more pathogenic when the relative abundance of this clone in isolates causing infections is higher compared to isolates associated with colonisation. Therefore, articles on pathogenicity of *E. coli* ST131 or *K. pneumoniae* ST258 should report the prevalence or incidence of infections among patients colonised with *E. coli* ST131 or *K. pneumoniae* ST258, the prevalence of *E. coli* ST131 or *K. pneumoniae* ST258 among patients colonised with *E. coli* or *K. pneumoniae*, respectively, or the prevalence of *E. coli* ST131 or *K. pneumoniae* ST258 among at least 10 clinical isolates of *E. coli* or *K. pneumoniae*, respectively.

Articles were excluded if they did not contain original data (such as reviews, commentaries, or articles reusing existing data sets), if they considered *E. coli* or *K. pneumoniae* only in non-human sources, or if there was no clear information on the isolate collection or selection.

Data extraction

Data were extracted by the same two reviewers independently, and crosschecked using a standard form developed by the researchers. Data were collected on population and setting, recording if participants were inpatients, outpatients/community residents, travellers or from another/unknown group. The area/region where the study took place was recorded and categorised into (mainly) from Africa, Asia, Australia, Europe, North America and South America. It was recorded whether data collection took place during an outbreak period, and if a selection on antibiotic susceptibility or resistance was made, divided into selection on ESBL/AmpC-producing isolates (including third-generation cephalosporin-resistant isolates), carbapenem-resistant or carbapenemase-producing Enterobacteriaceae (CRE/CPE, eg, KPC, OXA-48), other resistance profiles (eg, ciprofloxacin-resistant, fluoroquinolone-susceptible or multidrug resistant), or no selection on resistance. Furthermore, the method to detect sequence types was documented, split up into multilocus sequence typing

(MLST, when all isolates were typed by MLST), extrapolation based on pulsed-field gel electrophoresis (PFGE, when only selected isolates were typed with MLST and the sequence types were inferred based on PFGE type), (PCR, when all isolated underwent PCR-screening for ST-specific alleles), extrapolation based on PCR (mainly MLST for *E. coli* isolates that were positive for O25b-ST131 by PCR), or other/unknown (such as *fumC/fimH* typing). Also, the sample site of the included isolates (percentage of isolates isolated from blood, urine, gastrointestinal, respiratory, wound/abscess or other sites), and time period of the study were recorded. For the time period, the middle date was used in the model if the study covered a longer time period.

For transmissibility, if available, information was gathered on admission prevalence, number of cases, number of uncolonised patients and transmission measure given. For duration of colonisation, the number of cases and duration of colonisation was recorded. For pathogenicity, information was collected on the prevalence or incidence of infections in patients colonised with *E. coli* ST131 or *K. pneumoniae* ST258, the prevalence of *E. coli* ST131 or *K. pneumoniae* ST258 in patients colonised with *E. coli* or *K. pneumoniae*, respectively, and/or the prevalence of *E. coli* ST131 or *K. pneumoniae* ST258 in patients infected with *E. coli* or *K. pneumoniae*, respectively.

Quality of the included articles was assured by only including papers with a proper selection of isolates. Furthermore, quality was implicitly incorporated in the data that were collected on the detection method used, the sample sites, whether data were collected during an

outbreak and the setting and time period in which data were collected.

Several studies allowed splitting the data into multiple 'data sources'. For example, if data was available per year or per country, these were recorded separately. Figure 2 shows a flow diagram with the included and excluded articles. Since only 19 data sources were available on transmissibility (9 on *E. coli* ST131 and 10 on *K. pneumoniae* ST258), and two on duration of colonisation (both on *E. coli* ST131), we could only describe these without quantifying summary measures. For pathogenicity, enough data was available on *E. coli* to do a meta-regression analysis and calculate summary measures.

Meta-regression pathogenicity

In order to evaluate the pathogenicity of *E. coli* ST131 and *K. pneumoniae* ST258, and to assess which factors influence this, meta-regression was performed using all reported data on the prevalence of *E. coli* ST131 in clinical (infection) or screening (colonisation) isolates of *E. coli*, and for all reported data on the prevalence of *K. pneumoniae* ST258 in clinical (infection) isolates of *K. pneumoniae*. The prevalence estimates (calculated as the number of ST131-positive or ST258-positive isolates divided by the total number of *E. coli* or *K. pneumoniae* isolates, respectively) and standard errors (SEs) were logit transformed in the analysis. Heterogeneity between studies was evaluated with Cochran's Q and the I^2 statistic.¹² Because of high heterogeneity ($I^2 > 75\%$), a meta-analysis using a generalised linear

Figure 2 Flow chart of article selection.

mixed-effect model with random effects per data source was used to assess sources of variability in the overall prevalence estimates. Univariate analyses were performed to identify covariates associated with the overall prevalence estimates. All covariates with a p value <0.20 were included in the multivariate model, and backward selection was performed using the likelihood ratio test. There, as we are performing an exploratory analysis, a cut-off of $p < 0.10$ was used to determine statistical significance. The variable describing sample site was not included in the models, because of great dependency on the type of isolate (clinical or screening isolate, eg, blood isolates representing infection), and the effect of culture site, might not be comparable for isolates representing colonisation or infection. The estimated between-study variance (τ^2) was evaluated for the model with and without explanatory parameters. The exponent of the coefficient for colonisation/infection found in the metaregression model is an OR, which can be interpreted as a risk ratio. This was taken as a measure of how much more pathogenic *E. coli* ST131 was compared to non-ST131, that is, a value of 2 would indicate that per colonised day colonisation with ST131 leads two times more often to an infection as compared to colonisation with non-ST131. All analyses were performed in R V.3.0.3 (<http://CRAN.R-project.org>) using the 'metafor' package.

RESULTS

In all, 345 useful data sources were identified (see figure 2 for the consecutive steps followed for identification). For transmissibility, 19 data sources were identified; for duration of carriage, 2; and for pathogenicity, 324. Most studies ($n=206$, 72%) were performed in Europe and North America, and 266 (93%) were performed in a non-outbreak setting (table 1). *E. coli* isolates were most selected on ESBL production or resistance against third-generation cephalosporins, and *K. pneumoniae* isolates on being CRE/CPE. Colonisation isolates were most often from gastrointestinal origin (85.2%), and infection isolates from urine (54.8%) or blood (24.5%).

Transmissibility

There were 19 studies reporting transmissibility of *E. coli* ST131 ($n=9$) and *K. pneumoniae* ST258 ($n=10$), some being case reports or describing single possible transmission events (table 2). Transmission events for *E. coli* ST131 have been described or suggested in household ($n=4$), day care ($n=1$), nursing home ($n=1$) and hospital settings ($n=4$). For *K. pneumoniae* ST258 all sources reported on transmission events in hospital settings, and all included CRE/CPE.

Transmissibility can be quantified by the number of transmissions per patient, or patient-days at risk, which requires information on the number of index cases, number of transmissions, and number of days or

patients at risk. Yet, one or more of these aspects, especially time at risk, is missing in all studies but one. Most studies are cross-sectional studies, in which transmission cannot be proven.

Differences in transmission capacity between *E. coli* ST131 and non-ST131, or between *K. pneumoniae* ST258 and non-ST258, have not been quantified, precluding any conclusion on the relative transmissibility of *E. coli* ST131 and *K. pneumoniae* ST258 compared to other clonal lineages.

Duration of carriage

The duration of carriage of *E. coli* ST131 was investigated in two studies. In one study, colonisation with *E. coli* was still apparent after 12 months in 64% ($n=9$), and 40% ($n=14$) of those carrying *E. coli* ST131 or other STs, respectively ($p=0.12$).³² In another study, of two patients acquiring colonisation with *E. coli* ST131 during travel, one was a prolonged carrier with this strain. However, the definition of prolonged carriage was not given.³³ The duration of carriage of *K. pneumoniae* ST258 has not been determined.

Pathogenicity

E. coli

From 285 data sources, we retrieved data from 34 253 *E. coli* isolates (2041 associated with colonisation and 32 212 with infection). Prevalence of *E. coli* ST131 in these studies ranged from 0% to 100% (see online supplementary figure S1), with high statistical heterogeneity between studies ($I^2=96.9\%$).

In univariable meta-regression the *E. coli* ST131 prevalence in individual studies increased in time, and appeared to be influenced by whether isolates were associated with infection or colonisation, resistance patterns used for isolate selection and location, where the study was performed (p value <0.20 ; table 3). These variables were included in the multivariable meta-regression model, and time, location and selection remained significantly associated with *E. coli* ST131 prevalence (table 4). No significant effects were present for study population, microbiological methods used to detect ST131, or whether the study was performed in an outbreak situation or not.

The prevalence of ST131 was highest if *E. coli* isolates were selected upon the presence of ESBL production, or third-generation cephalosporin resistance, and lowest if derived from non-selective media. Prevalence of *E. coli* ST131 was highest in North America, and lowest in South America. The estimated prevalence of ST131 in *E. coli*, given particular values of the covariates, can be derived from the regression equation (table 4). For example, the estimated logit (prevalence ST131) for isolates causing infection, selected on presence of ESBL, in North America in January 2010 is given by $2.9668 + 12 \times 0.0140 + 1.1545 + 1.3826 + 0.4436 = 0.1819$, which corresponds to a prevalence of ST131 of $\exp(0.1819) / (1 + \exp(0.1819)) = 54.5\%$. The estimated prevalence in the

Table 1 Characteristics of included studies

	EC transmissibility (n=9)	KP transmissibility (n=10)	EC duration (n=2)	EC pathogenicity colonisation (n=35)	EC pathogenicity infection (n=249)	KP pathogenicity colonisation (n=3)	KP pathogenicity infection (n=35)	KP pathogenicity colonisation and infection (n=1)
Number of isolates (mean, SD)				58 (67)	129 (357)	59 (69)	40 (64)	
Number of isolates (median, IQR)				36 (21–62)	53 (20–115)	36 (20–87)	20 (14–41)	
Population—inpatients	2 (22.2%)	8 (80.0%)	1 (50.0%)	11 (31.4%)	128 (51.4%)	3 (100.0%)	24 (68.6%)	0 (0.0%)
Population—outpatients/ community	6 (66.7%)	2 (20.0%)	0 (0.0%)	18 (51.4%)	25 (10.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Population—mixed	1 (11.1%)	0 (0.0%)	0 (0.0%)	2 (5.7%)	63 (25.3%)	0 (0.0%)	2 (5.7%)	1 (100.0%)
Population—travellers	0 (0.0%)	0 (0.0%)	1 (50.0%)	3 (8.6%)	3 (1.2%)	0 (0.0%)	1 (2.9%)	0 (0.0%)
Population—other/unknown	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	30 (12.0%)	0 (0.0%)	9 (25.7%)	0 (0.0%)
Continent—Africa	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (5.7%)	16 (6.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Continent—Asia	2 (22.2%)	0 (0.0%)	0 (0.0%)	9 (25.7%)	42 (16.9%)	0 (0.0%)	4 (11.4%)	0 (0.0%)
Continent—Australia	0 (0.0%)	0 (0.0%)	1 (50.0%)	3 (8.6%)	10 (4.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Continent—Europe	4 (44.4%)	7 (70.0%)	1 (50.0%)	14 (40.0%)	96 (38.6%)	2 (66.7%)	14 (40.0%)	0 (0.0%)
Continent—North America	3 (33.3%)	1 (10.0%)	0 (0.0%)	7 (20.0%)	79 (31.7%)	1 (33.3%)	11 (31.4%)	1 (100.0%)
Continent—South America	0 (0.0%)	2 (20.0%)	0 (0.0%)	0 (0.0%)	6 (2.4%)	0 (0.0%)	6 (17.1%)	0 (0.0%)
Outbreak setting	3 (33.3%)	10 (100.0%)	0 (0.0%)	1 (2.9%)	4 (1.6%)	1 (33.3%)	8 (22.9%)	0 (0.0%)
Selection—ESBL/3GC-R	8 (88.9%)	0 (0.0%)	1 (50.0%)	23 (65.7%)	182 (73.1%)	2 (66.7%)	0 (0.0%)	0 (0.0%)
Selection—CRE/CPE	0 (0.0%)	9 (90.0%)	0 (0.0%)	0 (0.0%)	8 (3.2%)	1 (33.3%)	29 (82.9%)	1 (100.0%)
Selection—other	1 (11.1%)	0 (0.0%)	1 (50.0%)	5 (14.3%)	31 (12.4%)	0 (0.0%)	5 (14.3%)	0 (0.0%)
Selection—none	0 (0.0%)	1 (10.0%)	0 (0.0%)	7 (20.0%)	28 (11.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Detection—MLST	6 (66.7%)	4 (40.0%)	0 (0.0%)	10 (28.6%)	134 (53.8%)	1 (33.3%)	25 (71.4%)	0 (0.0%)
Detection—extrapolation based on PFGE	1 (11.1%)	3 (30.0%)	0 (0.0%)	3 (8.6%)	15 (6.0%)	1 (33.3%)	9 (25.7%)	1 (100.0%)
Detection—extrapolation based on PCR	2 (22.2%)	0 (0.0%)	2 (100.0%)	21 (60.0%)	83 (33.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Detection—CH	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	13 (5.2%)	1 (33.3%)	0 (0.0%)	0 (0.0%)
Detection—other/unknown	0 (0.0%)	2 (20.0%)	0 (0.0%)	1 (2.9%)	4 (1.6%)	0 (0.0%)	1 (2.9%)	0 (0.0%)
Site—blood	1 (11.1%)	3 (30.0%)	0 (0.0%)	0 (0.0%)	64 (25.7%)	0 (0.0%)	7 (20.0%)	0 (0.0%)
Site—urine	2 (22.2%)	3 (30.0%)	1 (50.0%)	2 (5.7%)	143 (57.4%)	1 (33.3%)	12 (34.3%)	1 (100.0%)
Site—gastrointestinal tract	6 (66.7%)	3 (30.0%)	1 (50.0%)	32 (91.4%)	5 (2.0%)	1 (33.3%)	7 (20.0%)	0 (0.0%)
Site—respiratory tract	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (2.9%)	3 (1.2%)	1 (33.3%)	3 (8.6%)	0 (0.0%)
Site—wound	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Site—other/unknown	0 (0.0%)	1 (10.0%)	0 (0.0%)	0 (0.0%)	33 (13.3%)	0 (0.0%)	6 (17.1%)	0 (0.0%)

CH, *fumC/fimH* typing; CPE, carbapenemase-producing Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; EC, *Escherichia coli*; ESBL, extended-spectrum beta-lactamase; KP, *Klebsiella pneumoniae*; KPC, *Klebsiella pneumoniae* carbapenemase; MLST, multilocus sequence typing; PFGE, pulsed-field gel electrophoresis; Site, site from which most isolates were identified.

Table 2 Summary of articles describing transmissibility of *Escherichia coli* ST131 and *Klebsiella pneumoniae* ST258

Author (year)	Country	Year	Setting	Organism	Resistance mechanism	Index cases (n)	Secondary cases (n)	Uncolonised	Exposure time
Veenemans (2014) ¹³	The Netherlands	2013	Nursing homes	<i>E. coli</i> ST131	ESBL	5 and 3			
Kojima (2014) ¹⁴	Japan	2009–2010	Household	<i>E. coli</i> ST131	ESBL	1	2		
Blanc (2014) ¹⁵	France	2012	Day care centers	<i>E. coli</i> ST131	ESBL	7			
Giuffrè (2013) ¹⁶	Italy	2012	Neonatal intensive care unit	<i>E. coli</i> ST131	ESBL	15		88	
Adler (2012) ¹⁷	Israel	2008–2009	Geriatric rehabilitation wards	<i>E. coli</i> ST131	ESBL	21	23	367	
Hilty (2012) ¹⁸	Switzerland	2008–2010	University hospital	<i>E. coli</i> non-ST131	ESBL	31	36	367	48 index inpatients for a total of 400 000 patient-days
				<i>E. coli</i> ST131	ESBL	13	2	36	
				<i>E. coli</i> non-ST131	ESBL	27	2	48	
Owens (2011) ¹⁹	USA	Before 2011	Household	<i>E. coli</i> ST131	ESBL	15	7	19	
				<i>E. coli</i> non-ST131	ESBL	42	13	49	
				<i>E. coli</i> ST131	ESBL	2			
Johnson (2010) ²⁰	USA	Before 2010	Household	<i>E. coli</i> ST131	Fluoro-quinolone resistance	1	1	1	
Ender (2009) ²¹	USA	Before 2009	Hospital	<i>E. coli</i> ST131	ESBL	1	1		
Marquez (2014) ²²	Uruguay	2011	Intensive care unit	<i>K. pneumoniae</i> ST258	KPC	1	1	3	
Garza-Ramos (2014) ²³	Mexico	2012–2013	2 Hospitals	<i>K. pneumoniae</i> ST258	KPC	15 and 3			
Gaibani (2014) ²⁴	Italy	2010	Hospital	<i>K. pneumoniae</i> ST258	KPC	11			
Giuffrè (2013) ²⁵	Italy	2012	Neonatal intensive care unit	<i>K. pneumoniae</i> ST258	KPC	10		44	
Tofteland (2013) ²⁶	Norway	2010	Intensive care unit	<i>K. pneumoniae</i> ST258	KPC	6			
Morris (2012) ²⁷	Ireland	2011	2 Hospitals	<i>K. pneumoniae</i> ST258	KPC	11			
Agodi (2011) ²⁸	Italy	2009	Hospital	<i>K. pneumoniae</i> ST258	KPC	16			
Won (2011) ²⁹	USA	2008	Acute care hospitals and long-term acute care hospitals	<i>K. pneumoniae</i> ST258	KPC	33 (+7 presumed cases)			
Marchese (2010) ³⁰	Italy	2009	Neuro-rehabilitation unit	<i>K. pneumoniae</i> ST258	KPC	4 (+3 at time of publication)			
Mammìna (2010) ³¹	Italy	2009	Intensive care unit	<i>K. pneumoniae</i> ST258	KPC	13			

Table 3 Effect of covariates on prevalence of ST131 in *Escherichia coli* (univariable random effects meta-regression models)

	p Value
Study period (per month*)	0.0011
Infection or colonisation	0.0002
Colonisation	
Infection	
Outbreak setting	0.9112
Selection of isolates based on resistance pattern	<0.0001
No selection on resistance profile	
ESBL/3GC-R	
CRE/CPE	
Other	
Study population	0.6219
Inpatients	
Outpatients/community	
Mixed	
Travellers	
Other/unknown	
Location	<0.0001
Europe	
North America	
South America	
Australia	
Asia	
Africa	
Method used to detect ST131	0.3598
MLST	
Extrapolation based on PFGE	
PCR	
Extrapolation based on PCR	
Other/unknown	

*Reference date: 1 January 2009.
 CRE/CPE, carbapenem-resistant Enterobacteriaceae/
 carbapenemase-producing Enterobacteriaceae; ESBL/3GC-R,
 extended-spectrum β -lactamases/third-generation cephalosporin
 resistance; MLST, multi-locus sequence typing; PFGE,
 pulsed-field gel electrophoresis.

reference category (January 2009, colonisation, no selection on resistant profile, Europe) is $\exp(-2.9668)/(1 + \exp(-2.9668)) = 4.9\%$.

In the multivariable meta-regression model, *E. coli* ST131 was significantly associated with infection compared to colonisation, suggesting that ST131 isolates are more pathogenic than non-ST131 isolates. From the infection/colonisation coefficient, we can calculate the relative pathogenicity of *E. coli* ST131 compared to non-ST131. We found that *E. coli* ST131 is 3.2 (95% CI 2.0 to 5.0) times more pathogenic than non-ST131. Online supplementary figure S2 shows the proportion of ST131 found in infection isolates compared to colonisation isolates as estimated by the meta-regression model.

The estimated between-study variance (τ^2) reduced from 1.68 in the model without parameters to 1.1 in the final model, implying that a high level of heterogeneity remained.

Table 4 Effect of covariates on prevalence of ST131 in *Escherichia coli* (multivariable random effects meta-regression model)

	Estimate (SE*)	p Value
Intercept	-2.9668 (0.2959)	
Study period (per month†)	0.0140 (0.0023)	<0.0001
Infection or colonisation		<0.0001
Colonisation	Reference	
Infection	1.1545 (0.2281)	
Selection of isolates based on resistance pattern		<0.0001
No selection on resistance profile	Reference	
ESBL/3GC-R	1.3826 (0.2207)	
CRE/CPE	0.5994 (0.4879)	
Other	0.9058 (0.2709)	
Location		<0.0001
Europe	Reference	
North America	0.4436 (0.1675)	
South America	-2.2868 (0.6101)	
Australia	-0.4209 (0.3407)	
Asia	-0.3657 (0.1927)	
Africa	-0.2246 (0.3154)	

*Parameter estimates (SEs) are presented on a logit scale.

†Reference date: 1 January 2009.

CRE/CPE, carbapenem-resistant Enterobacteriaceae/
 carbapenemase-producing Enterobacteriaceae; ESBL/3GC-R,
 extended-spectrum β -lactamases/third-generation cephalosporin
 resistance.

K. pneumoniae

There were 35 and three data sources providing information on the prevalence of ST258 *K. pneumoniae* in clinical and colonising isolates, respectively (see online supplementary figure S3). Because of limited data on colonisation, quantitative analyses were performed for clinical isolates only.

In the univariable meta-regression model, outbreak setting yes/no, selection of isolates based on resistance pattern, study population and geographic location were all associated with a higher prevalence of ST258 with a p value <0.20 and were, thus, included in the multivariable model (table 5). If data were collected during an outbreak of *K. pneumoniae*, this was associated with a higher prevalence of ST258 (table 6). Furthermore, the model yielded a significant effect of resistance patterns on the prevalence of ST258 in *K. pneumoniae*. ST258 prevalence was associated with selection of isolates on CRE-positivity, but the number of data sources describing isolates that are not CRE/CPE is low and varied (n=5). Furthermore, study population characteristics also appeared to influence ST258 prevalence in *K. pneumoniae*, with higher prevalence of ST258 in inpatients, compared to 'other' populations. Yet, the 'other' group is not defined accurately, precluding firm conclusions. Only one data source was available for outpatients or persons residing in the community. Finally, the reported ST258 prevalence was lower in Asia and Australia than in other continents.

Table 5 Effect of covariates on prevalence of ST258 in clinical isolates of *Klebsiella pneumoniae* (univariable random effects meta-regression models)

	p Value
Study period (per month*)	0.6109
Outbreak setting	0.0052
Selection of isolates based on resistance pattern	0.0543
Non-CRE/CPE	
CRE/CPE	
Study population	0.0265
Inpatients	
Mixed	
Other/unknown	
Location	0.1013
Europe	
North America	
South America	
Asia (including Australia)	
Method used to detect ST258	0.2253
MLST	
Extrapolation based on PFGE	

*Reference date: 1 January 2009.

CRE/CPE, carbapenem-resistant Enterobacteriaceae/ carbapenemase-producing Enterobacteriaceae; MLST, multi-locus sequence typing; PFGE, pulsed-field gel electrophoresis.

The estimated prevalence of ST258 in *K. pneumoniae*, given particular values of the covariates, can be derived from the regression equation. For example, the estimated logit (prevalence of ST258) for isolates selected on presence of CRE in hospital inpatients in North America during an outbreak is given by -0.0320

Table 6 Effect of covariates on prevalence of ST258 in clinical isolates of *Klebsiella pneumoniae* (multivariable random effects meta-regression model)

	Estimate (SE*)	p Value
Intercept	-0.0320 (1.0008)	0.9745
Outbreak setting		<0.05
Yes	Reference	
No	-1.7725 (0.7833)	
Selection of isolates based on resistance pattern		<0.01
Non-CRE/CPE	Reference	
CRE/CPE	2.8038 (0.9445)	
Study population		<0.01
Inpatients	Reference	
Mixed	-3.8232 (1.5480)	
Other/unknown	-2.2908 (0.7255)	
Location		<0.05
Europe	Reference	
North America	0.3332 (0.7607)	
South America	0.4213 (0.9038)	
Asia (including Australia)	-2.0716 (0.7833)	

*Parameter estimates (SEs) are presented on a logit scale.

CRE/CPE, carbapenem-resistant Enterobacteriaceae/ carbapenemase-producing Enterobacteriaceae.

$+2.8038+0.3332=3.1050$, which corresponds to a prevalence of ST258 of $\exp(3.1050)/(1+\exp(3.1050))=95.7\%$. The estimated prevalence in the reference category (during an outbreak, non CRE/CPE, hospital inpatients, Europe) is $\exp(-0.0320)/(1+\exp(-0.0320))=50.8\%$.

The estimated between-study variance (τ^2) reduced from 6.43 in the model without parameters to 2.25 in the final model, indicating a considerable improvement, but still a high level of heterogeneity.

ST258 was not detected in two studies reporting on colonisation with *K. pneumoniae*, that included 36 and 4 isolates, respectively.^{184 219} Only from the study of van Duin *et al.*²²⁴ can we deduce a prevalence of ST258 in *K. pneumoniae* of 31% in colonising isolates. This precludes any quantification of the pathogenicity of *K. pneumoniae* ST258.

The only study in which both colonisation and infection with *K. pneumoniae* ST258 were investigated included a set of seven KPC-producing *K. pneumoniae* ST258 isolates collected from a long-term acute-care facility in South Florida.²⁴⁵ Three patients were colonised, and four had both colonisation and infection. Again, the sample size is too small for drawing conclusions.

DISCUSSION

Based on published information, we conclude that there is evidence that *E. coli* ST131 is more pathogenic than *E. coli* non-ST131, but not for increased transmissibility or prolonged duration of carriage. Because of the heterogeneity in the data, it cannot be concluded (nor rejected) that *E. coli* ST131 is a hyperendemic clone. For *K. pneumoniae* ST258, the published data precluded any conclusion on increased transmissibility, longer duration of carriage or increased pathogenicity.

Several limitations in our study should be acknowledged. Because of our search strategy, the prevalence of *E. coli* ST131 and *K. pneumoniae* ST258 that were retrieved are likely overestimations of the real prevalence. We required the articles to report ST131/ST258 in their title and/or abstract, and therefore, articles that did not report this, or that did not detect ST131/ST258 in their study, may have been missed. Since the prevalence is dependent on factors including time, location, resistance pattern, population studied and possibly variables not included in this review (eg, patient-specific details like age, gender), we deemed it not meaningful to estimate an overall prevalence of ST131 in *E. coli* or ST258 in *K. pneumoniae*.

We also did not create a funnel plot to assess publication bias, as such an analysis also assumes that there is one overall effect or prevalence. Thus, publication bias cannot be excluded. It is possible that identification of *E. coli* ST131 or *K. pneumoniae* ST258 stimulates publication because of the current interest in these clones. However, this will most likely equally influence studies reporting infection and colonisation isolates, which

would not influence our conclusions. Also, the finding of ESBL or KPC might instigate investigation of sequence types. As 70% of the included studies on *E. coli* selected isolates based on the presence of ESBL or 3GC-R, our findings might be more applicable to ESBL-producing *E. coli* ST131 than all *E. coli* ST131 in general. The same holds for *K. pneumoniae*, for which around 90% of included studies selected isolates based on the presence of carbapenemase production of carbapenem resistance, mainly corresponding to KPC production. In our analysis, we used grouped variables (eg, continent instead of country), as there are limitations to the number of variables that can be studied.

There could also be differences in detecting infection and colonisation-associated isolates. Infection isolates are mainly collected retrospectively, when a pattern or outbreak is recognised, whereas, colonisation isolates are more often collected prospectively. Yet, since determination of sequence types is unambiguous, it is unlikely that such differences have affected our conclusions.

Our analysis clearly demonstrates that more—and better designed—studies are needed to determine whether *E. coli* ST131 and *K. pneumoniae* ST258 are truly hyperendemic clones. This would be possible with a prospective cohort study of a population (eg, the general population or hospitalised patients) with a certain contact structure, in which carriage with *E. coli* or *K. pneumoniae* is regularly (eg, weekly or monthly) determined. As *K. pneumoniae* ST258 is mainly a healthcare-associated pathogen, choice of study population might be different than for *E. coli* ST131, that is also a community-associated pathogen. For determination of transmissibility, genotyping should be performed, preferably with highly discriminatory methods, and preferably with inclusion of multiple isolates per patient.²⁴⁶ The duration of exposure to persons colonised or infected with *E. coli* ST131/*K. pneumoniae* ST258 should be determined to calculate the number of acquisitions per unit of time. Carriers could be studied in more detail to determine the duration of carriage and the infection rate (and duration until infection), preferably with inclusion of the effects of antibiotic use on these parameters. There should be a sufficient duration of follow-up, and isolates should be characterised to determine whether multiple isolates represent persistent carriage or recolonisation with different strains.

In conclusion, current evidence does not allow the conclusion that *E. coli* ST131 and *K. pneumoniae* ST258 are hyperendemic clones.

Contributors MJDD and MRH performed the systematic literature search, reviewed and summarised data from each selected article, performed the analyses and wrote the first draft of the manuscript. MJDD, MRH, MJMB and MCJB all revised the manuscript.

Funding European Community (RGNOIS Integrated project [FP7/2007-2013] under grant agreement no. 282512 to MRH, MJMB and MCJB; Netherlands Organization of Scientific Research (VICI NWO Grant 918.76.611 to MJMB

and Priority Medicines Antimicrobial Resistance grant 205100013 to MRH and MCJB).

Competing interests None declared.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

REFERENCES

1. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, *et al.* Intercontinental emergence of *Escherichia coli* clone O25:H4-ST131 producing CTX-M-15. *J Antimicrob Chemother* 2008;61:273–81.
2. Samuelsen Ø, Naseer U, Tofteland S, *et al.* Emergence of clonally related *Klebsiella* isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. *J Antimicrob Chemother* 2009;63:654–8.
3. Nicolas-Chanoine MH, Bertrand X, Madec JY. *Escherichia coli* ST131, an Intriguing Clonal Group. *Clin Microbiol Rev* 2014;27:543–74.
4. Rogers BA, Sidjabat HE, Paterson DL. *Escherichia coli* O25b-ST131: a pandemic, multiresistant, community-associated strain. *J Antimicrob Chemother* 2011;66:1–14.
5. Banerjee R, Johnson JR. A new clone sweeps clean: the enigmatic emergence of *Escherichia coli* sequence type 131. *Antimicrob Agents Chemother* 2014;58:4997–5004.
6. Woodford N, Turtton JF, Livermore DM. Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistance. *FEMS Microbiol Rev* 2011;35:736–55.
7. Kitchel B, Rasheed JK, Patel JB, *et al.* Molecular epidemiology of KPC-producing *Klebsiella pneumoniae* isolates in the United States: clonal expansion of multilocus sequence type 258. *Antimicrob Agents Chemother* 2009;53:3365–70.
8. Grundmann H, Livermore DM, Giske CG, *et al.* CNSE Working Group. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. *Euro Surveill* 2010;15:pii: 19711. <http://www.ncbi.nlm.nih.gov/pubmed/21144429> (accessed 20 May 2015).
9. Rogers BA, Doi Y. Who is leading this dance? Understanding the spread of *Escherichia coli* sequence type 131. *Infect Control Hosp Epidemiol* 2013;34:370–2.
10. Bonten MJ, Weinstein RA. The role of colonization in the pathogenesis of nosocomial infections. *Infect Control Hosp Epidemiol* 1996;17:193–200.
11. Stroup DF, Berlin JA, Morton SC, *et al.* Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* 2000;283:2008–12. <http://www.ncbi.nlm.nih.gov/pubmed/10789670> (accessed 28 Mar 2015).
12. Higgins JPT, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557–60.
13. Veenemans J, Overvest IT, Snelders E, *et al.* Next-generation sequencing for typing and detection of resistance genes: performance of a new commercial method during an outbreak of extended-spectrum-beta-lactamase-producing *Escherichia coli*. *J Clin Microbiol* 2014;52:2454–60.
14. Kojima Y, Harada S, Aoki K, *et al.* Spread of CTX-M-15 extended-spectrum β -lactamase-producing *Escherichia coli* isolates through household contact and plasmid transfer. *J Clin Microbiol* 2014;52:1783–5.
15. Blanc V, Leflon-Guibout V, Blanco J, *et al.* Prevalence of day-care centre children (France) with faecal CTX-M-producing *Escherichia coli* comprising O25b:H4 and O16:H5 ST131 strains. *J Antimicrob Chemother* 2014;69:1231–7.
16. Giuffrè M, Cipolla D, Bonura C, *et al.* Outbreak of colonizations by extended-spectrum β -lactamase-producing *Escherichia coli* sequence type 131 in a neonatal intensive care unit, Italy. *Antimicrob Resist Infect Control* 2013;2:8.
17. Adler A, Gniadkowski M, Baraniak A, *et al.* Transmission dynamics of ESBL-producing *Escherichia coli* clones in rehabilitation wards at a tertiary care centre. *Clin Microbiol Infect* 2012;18:E497–505.

18. Hilty M, Betsch BY, Bögli-Stuber K, *et al.* Transmission dynamics of extended-spectrum β -lactamase-producing Enterobacteriaceae in the tertiary care hospital and the household setting. *Clin Infect Dis* 2012;55:967–75.
19. Owens RC, Johnson JR, Stogsdill P, *et al.* Community transmission in the United States of a CTX-M-15-producing sequence type ST131 *Escherichia coli* strain resulting in death. *J Clin Microbiol* 2011;49:3406–8.
20. Johnson JR, Anderson JT, Clabots C, *et al.* Within-household sharing of a fluoroquinolone-resistant *Escherichia coli* sequence type ST131 strain causing pediatric osteoarticular infection. *Pediatr Infect Dis J* 2010;29:473–5.
21. Ender PT, Gajanana D, Johnston B, *et al.* Transmission of an extended-spectrum-beta-lactamase-producing *Escherichia coli* (sequence type ST131) strain between a father and daughter resulting in septic shock and Emphysematous pyelonephritis. *J Clin Microbiol* 2009;47:3780–2.
22. Marquez C, Ingold A, Echeverría N, *et al.* Emergence of KPC-producing *Klebsiella pneumoniae* in Uruguay: infection control and molecular characterization. *New microbes new Infect* 2014;2:58–63.
23. Garza-Ramos U, Barrios H, Reyna-Flores F, *et al.* Characteristics of KPC-2-producing *Klebsiella pneumoniae* (ST258) clinical isolates from outbreaks in 2 Mexican medical centers. *Diagn Microbiol Infect Dis* 2014;79:483–5.
24. Gaibani P, Colombo R, Arghittu M, *et al.* Successful containment and infection control of a Carbapenem-resistant *Klebsiella pneumoniae* outbreak in an Italian hospital. *New Microbiol* 2014;37:87–90. <http://www.ncbi.nlm.nih.gov/pubmed/24531175> (accessed 20 May 2015).
25. Giuffrè M, Bonura C, Geraci DM, *et al.* Successful control of an outbreak of colonization by *Klebsiella pneumoniae* carbapenemase-producing K. pneumoniae sequence type 258 in a neonatal intensive care unit, Italy. *J Hosp Infect* 2013;85:233–6.
26. Tøfteland S, Naseer U, Lisløvand JH, *et al.* A long-term low-frequency hospital outbreak of KPC-producing *Klebsiella pneumoniae* involving *Intergenus* plasmid diffusion and a persisting environmental reservoir. *PLoS ONE* 2013;8:e59015.
27. Morris D, Boyle F, Morris C, *et al.* Inter-hospital outbreak of *Klebsiella pneumoniae* producing KPC-2 carbapenemase in Ireland. *J Antimicrob Chemother* 2012;67:2367–72.
28. Agodi A, Voulgari E, Barchitta M, *et al.* Containment of an outbreak of KPC-3-producing *Klebsiella pneumoniae* in Italy. *J Clin Microbiol* 2011;49:3986–9.
29. Won SY, Munoz-Price LS, Lolans K, *et al.* Emergence and rapid regional spread of *Klebsiella pneumoniae* carbapenemase-producing Enterobacteriaceae. *Clin Infect Dis* 2011;53:532–40.
30. Marchese A, Coppo E, Barbieri R, *et al.* Emergence of KPC-2 carbapenemase-producing *Klebsiella pneumoniae* strains and spread of an isolate of sequence type 258 in the neuro-rehabilitation unit of an Italian hospital. *J Chemother* 2010;22:212–14.
31. Mammina C, Palma DM, Bonura C, *et al.* Outbreak of infection with *Klebsiella pneumoniae* sequence type 258 producing *Klebsiella pneumoniae* Carbapenemase 3 in an intensive care unit in Italy. *J Clin Microbiol* 2010;48:1506–7.
32. Tittelman E, Hasan CM, Iversen A, *et al.* Faecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae is common 12 months after infection and is related to strain factors. *Clin Microbiol Infect* 2014;20:O508–15.
33. Rogers BA, Kennedy KJ, Sidjabat HE, *et al.* Prolonged carriage of resistant *E. coli* by returned travellers: clonality, risk factors and bacterial characteristics. *Eur J Clin Microbiol Infect Dis* 2012;31:2413–20.
34. Papagiannitsis CC, Študentová V, Jakubů V, *et al.* High prevalence of ST131 among CTX-M-producing *Escherichia coli* from community-acquired infections, in the Czech Republic. *Microb Drug Resist* 2015;21:74–84.
35. Osawa K, Shigemura K, Shimizu R, *et al.* Molecular characteristics of extended-spectrum β -lactamase-producing *Escherichia coli* in a university teaching hospital. *Microb Drug Resist* 2015;21:130–9.
36. Hristea A, Olaru ID, Adams-Sapper S, *et al.* Characterization of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* from bloodstream infections in three hospitals in Bucharest, Romania: a preliminary study. *Infect Dis (Lond)* 2015;47:46–51.
37. Salipante SJ, Roach DJ, Kitzman JO, *et al.* Large-scale genomic sequencing of extraintestinal pathogenic *Escherichia coli* strains. *Genome Res* 2015;25:119–28.
38. Can F, Azap OK, Seref C, *et al.* Emerging *Escherichia coli* O25b/ST131 clone predicts treatment failure in urinary tract infections. *Clin Infect Dis* 2015;60:523–7.
39. Zhao L, Zhang J, Zheng B, *et al.* Molecular epidemiology and genetic diversity of fluoroquinolone-resistant *Escherichia coli* isolates from patients with community-onset infections in 30 Chinese county hospitals. *J Clin Microbiol* 2015;53:766–70.
40. Hansen F, Olsen SS, Heltberg O, *et al.* Characterization of third-generation cephalosporin-resistant *Escherichia coli* from bloodstream infections in Denmark. *Microb Drug Resist* 2014;20:316–24.
41. Berman H, Barberino MG, Moreira ED, *et al.* Distribution of strain type and antimicrobial susceptibility of *Escherichia coli* isolates causing meningitis in a large urban setting in Brazil. *J Clin Microbiol* 2014;52:1418–22.
42. Peirano G, Pitout JDD. Fluoroquinolone-resistant *Escherichia coli* sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. *Antimicrob Agents Chemother* 2014;58:2699–703.
43. Shakir SM, Goldbeck JM, Robison D, *et al.* Genotypic and phenotypic characterization of invasive neonatal *Escherichia coli* clinical isolates. *Am J Perinatol* 2014;31:975–82.
44. Peirano G, Ahmed-Bentley J, Fuller J, *et al.* Travel-related carbapenemase-producing Gram-negative bacteria in Alberta, Canada: the first 3 years. *J Clin Microbiol* 2014;52:1575–81.
45. Sana F, Mabrouka S, Claudine Q, *et al.* Prevalence and characterization of uropathogenic *Escherichia coli* harboring plasmid-mediated quinolone resistance in a Tunisian university hospital. *Diagn Microbiol Infect Dis* 2014;79:247–51.
46. Önnberg A, Söderquist B, Persson K, *et al.* Characterization of CTX-M-producing *Escherichia coli* by repetitive sequence-based PCR and real-time PCR-based replicon typing of CTX-M-15 plasmids. *APMIS* 2014;122:1136–43.
47. Oteo J, González-López JJ, Ortega A, *et al.* Spanish Network for Research in Infectious Diseases (REIPI). Inhibitor-resistant TEM- and OXA-1-producing *Escherichia coli* isolates resistant to amoxicillin-clavulanate are more clonal and possess lower virulence gene content than susceptible clinical isolates. *Antimicrob Agents Chemother* 2014;58:3874–81.
48. Rodríguez I, Thomas K, Van Essen A, *et al.* Chromosomal location of blaCTX-M genes in clinical isolates of *Escherichia coli* from Germany, The Netherlands and the UK. *Int J Antimicrob Agents* 2014;43:553–7.
49. O'Hara JA, Hu F, Ahn C, *et al.* Molecular epidemiology of KPC-producing *Escherichia coli*: occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIK plasmid. *Antimicrob Agents Chemother* 2014;58:4234–7.
50. Inwezerua C, Mendonça N, Calhau V, *et al.* Occurrence of extended-spectrum beta-lactamases in human and bovine isolates of *Escherichia coli* from Oyo state, Nigeria. *J Infect Dev Ctries* 2014;8:774–9. <http://www.ncbi.nlm.nih.gov/pubmed/24916877> (accessed 2 Nov 2015).
51. Mícenková L, Šišková P, Bosák J, *et al.* Characterization of Human Uropathogenic ESBL-Producing *Escherichia coli* in the Czech Republic: spread of CTX-M-27-Producing Strains in a University Hospital. *Microb Drug Resist* 2014;20:610–17.
52. Xia S, Fan X, Huang Z, *et al.* Dominance of CTX-M-type extended-spectrum β -lactamase (ESBL)-producing *Escherichia coli* isolated from patients with community-onset and hospital-onset infection in China. *PLoS ONE* 2014;9:e100707.
53. Morgand M, Vimont S, Bleibtreu A, *et al.* Extended-spectrum beta-lactamase-producing *Escherichia coli* infections in children: are community-acquired strains different from nosocomial strains? *Int J Med Microbiol* 2014;304:970–6.
54. Suwantarant N, Rudin SD, Marshall SH, *et al.* Infections caused by fluoroquinolone-resistant *Escherichia coli* following transrectal ultrasound-guided biopsy of the prostate. *J Glob Antimicrob Resist* 2014;2:71–6.
55. Maluta RP, Logue CM, Casas MRT, *et al.* Overlapped sequence types (STs) and serogroups of avian pathogenic (APEC) and human extra-intestinal pathogenic (ExPEC) *Escherichia coli* isolated in Brazil. *PLoS ONE* 2014;9:e105016.
56. Dashti AA, Vali L, El-Shazly S, *et al.* The characterization and antibiotic resistance profiles of clinical *Escherichia coli* O25b-B2-ST131 isolates in Kuwait. *BMC Microbiol* 2014;14:214.
57. Freeman JT, Rubin J, McAuliffe GN, *et al.* Differences in risk-factor profiles between patients with ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae*: a multicentre case-case comparison study. *Antimicrob Resist Infect Control* 2014;3:27.
58. Hussain A, Ranjan A, Nandanwar N, *et al.* Genotypic and phenotypic profiles of *Escherichia coli* isolates belonging to clinical sequence type 131 (ST131), clinical non-ST131, and fecal

- non-ST131 lineages from India. *Antimicrob Agents Chemother* 2014;58:7240–9.
59. Dahbi G, Mora A, Mamani R, *et al.* Molecular epidemiology and virulence of *Escherichia coli* O16:H5-ST131: comparison with H30 and H30-Rx subclones of O25b:H4-ST131. *Int J Med Microbiol* 2014;304:1247–57.
 60. Zhang J, Zheng B, Zhao L, *et al.* Nationwide high prevalence of CTX-M and an increase of CTX-M-55 in *Escherichia coli* isolated from patients with community-onset infections in Chinese county hospitals. *BMC Infect Dis* 2014;14:659.
 61. Usein CR, Condei M, Cristea D, *et al.* *Escherichia coli* ST131 causing invasive infections in Romanian patients—a threat we can no longer ignore. *Roum Arch Microbiol Immunol* 2014;73:5–8. <http://www.ncbi.nlm.nih.gov/pubmed/25518564> (accessed 23 Nov 2015).
 62. Wu YH, Cheng MF, Lai CH, *et al.* The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing *Escherichia coli* bacteraemia. *BMC Infect Dis* 2014;14:579.
 63. Guillard T, Bertrand X, de Champs C, *et al.* *Aac(6')Ib-cr* is the major plasmid-mediated quinolone resistance determinant in extended-spectrum beta-lactamase-producing *Escherichia coli* in Eastern France. *J Global Antimicrob Resist* 2014;2:111–13.
 64. Habeeb MA, Haque A, Iversen A, *et al.* Occurrence of virulence genes, 16S rRNA methylases, and plasmid-mediated quinolone resistance genes in CTX-M-producing *Escherichia coli* from Pakistan. *Eur J Clin Microbiol Infect Dis* 2014;33:399–409.
 65. López-Cerero L, Navarro MD, Bellido M, *et al.* *Escherichia coli* belonging to the worldwide emerging epidemic clonal group O25b/ST131: risk factors and clinical implications. *J Antimicrob Chemother* 2014;69:809–14.
 66. Giufre M, Accogli M, Farina C, *et al.* Predominance of the fimH30 subclone among multidrug-resistant *Escherichia coli* strains belonging to sequence type 131 in Italy. *J Infect Dis* 2014;209:629–30.
 67. Ferjani S, Saidani M, Ennigrou S, *et al.* Multidrug resistance and high virulence genotype in uropathogenic *Escherichia coli* due to diffusion of ST131 clonal group producing CTX-M-15: an emerging problem in a Tunisian hospital. *Folia Microbiol (Praha)* 2014;59:257–62.
 68. Al-Agamy MH, Shibli AM, Hafez MM, *et al.* Molecular characteristics of extended-spectrum β -lactamase-producing *Escherichia coli* in Riyadh: emergence of CTX-M-15-producing *E. coli* ST131. *Ann Clin Microbiol Antimicrob* 2014;13:4.
 69. Rogers BA, Ingram PR, Runnegar N, *et al.* Community-onset *Escherichia coli* infection resistant to expanded-spectrum cephalosporins in low-prevalence countries. *Antimicrob Agents Chemother* 2014;58:2126–34.
 70. Nicolas-Chanoine MH, Robert J, Vigan M, *et al.* Different factors associated with CTX-M-producing ST131 and non-ST131 *Escherichia coli* clinical isolates. *PLoS ONE* 2013;8:e72191.
 71. Nordberg V, Quizhpe Peralta A, Galindo T, *et al.* High proportion of intestinal colonization with successful epidemic clones of ESBL-producing Enterobacteriaceae in a neonatal intensive care unit in Ecuador. *PLoS ONE* 2013;8:e76597.
 72. Dimude JU, Amyes SGB. Molecular diversity associated with the dissemination of CTX-M-15 beta-lactamase gene in blood culture isolates of *Escherichia coli* from Edinburgh. *Scand J Infect Dis* 2013;45:32–7.
 73. Karfunkel D, Carmeli Y, Chmelnitsky I, *et al.* The emergence and dissemination of CTX-M-producing *Escherichia coli* sequence type 131 causing community-onset bacteremia in Israel. *Eur J Clin Microbiol Infect Dis* 2013;32:513–21.
 74. Nielsen JB, Albayati A, Jørgensen RL, *et al.* An abbreviated MLVA identifies *Escherichia coli* ST131 as the major extended-spectrum β -lactamase-producing lineage in the Copenhagen area. *Eur J Clin Microbiol Infect Dis* 2013;32:431–6.
 75. van der Donk CFM, Schols JMGA, Driessen CJ, *et al.* Prevalence and spread of multidrug resistant *Escherichia coli* isolates among nursing home residents in the southern part of The Netherlands. *J Am Med Dir Assoc* 2013;14:199–203.
 76. Adams-Sapper S, Diep BA, Perdreau-Remington F, *et al.* Clonal composition and community clustering of drug-susceptible and -resistant *Escherichia coli* isolates from bloodstream infections. *Antimicrob Agents Chemother* 2013;57:490–7.
 77. Doi Y, Park YS, Rivera JI, *et al.* Community-associated extended-spectrum β -lactamase-producing *Escherichia coli* infection in the United States. *Clin Infect Dis* 2013;56:641–8.
 78. López-Cerero L, Bellido Mdel M, Serrano L, *et al.* *Escherichia coli* O25b:H4/ST131 are prevalent in Spain and are often not associated with ESBL or quinolone resistance. *Enferm Infecc Microbiol Clin* 2013;31:385–8.
 79. Helldal L, Karami N, Florén K, *et al.* Shift of CTX-M genotypes has determined the increased prevalence of extended-spectrum β -lactamase-producing *Escherichia coli* in south-western Sweden. *Clin Microbiol Infect* 2013;19:E87–90.
 80. Hammami S, Saidani M, Ferjani S, *et al.* Characterization of extended spectrum β -lactamase-producing *Escherichia coli* in community-acquired urinary tract infections in Tunisia. *Microb Drug Resist* 2013;19:231–6.
 81. Kudinha T, Johnson JR, Andrew SD, *et al.* Distribution of phylogenetic groups, sequence type ST131, and virulence-associated traits among *Escherichia coli* isolates from men with pyelonephritis or cystitis and healthy controls. *Clin Microbiol Infect* 2013;19:E173–80.
 82. Kudinha T, Johnson JR, Andrew SD, *et al.* Genotypic and phenotypic characterization of *Escherichia coli* isolates from children with urinary tract infection and from healthy carriers. *Pediatr Infect Dis J* 2013;32:543–8.
 83. Weissman SJ, Adler A, Qin X, *et al.* Emergence of extended-spectrum β -lactam resistance among *Escherichia coli* at a US academic children's hospital is clonal at the sequence type level for CTX-M-15, but not for CMY-2. *Int J Antimicrob Agents* 2013;41:414–20.
 84. Banerjee R, Johnston B, Lohse C, *et al.* *Escherichia coli* sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts. *Infect Control Hosp Epidemiol* 2013;34:361–9.
 85. Kim B, Kim J, Seo MR, *et al.* Clinical characteristics of community-acquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. *Infection* 2013;41:603–12.
 86. Aoike N, Saga T, Sakata R, *et al.* Molecular characterization of extraintestinal *Escherichia coli* isolates in Japan: relationship between sequence types and mutation patterns of quinolone resistance-determining regions analyzed by pyrosequencing. *J Clin Microbiol* 2013;51:1692–8.
 87. Olesen B, Hansen DS, Nilsson F, *et al.* Prevalence and characteristics of the epidemic multiresistant *Escherichia coli* ST131 clonal group among extended-spectrum beta-lactamase-producing *E. coli* isolates in Copenhagen, Denmark. *J Clin Microbiol* 2013;51:1779–85.
 88. Qin X, Hu F, Wu S, *et al.* Comparison of adhesin genes and antimicrobial susceptibilities between uropathogenic and intestinal commensal *Escherichia coli* strains. *PLoS ONE* 2013;8:e61169.
 89. Denisuk AJ, Lagacé-Wiens PR, Pitout JD, *et al.* Canadian Antimicrobial Resistance Alliance. Molecular epidemiology of extended-spectrum β -lactamase-, AmpC β -lactamase- and carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from Canadian hospitals over a 5 year period: CANWARD 2007–11. *J Antimicrob Chemother* 2013;68(Suppl 1): i57–65.
 90. Yano H, Uemura M, Endo S, *et al.* Molecular characteristics of extended-spectrum β -lactamases in clinical isolates from *Escherichia coli* at a Japanese tertiary hospital. *PLoS ONE* 2013;8:e64359.
 91. Chmielarczyk A, Pobjega M, Wójkowska-Mach J, *et al.* Molecular epidemiology, plasmid analysis, virulence, and resistance of *Escherichia coli* isolated from neonatal intensive care units in Poland. *Diagn Microbiol Infect Dis* 2013;76:542–5.
 92. Seiffert SN, Hilty M, Kronenberg A, *et al.* Extended-spectrum cephalosporin-resistant *Escherichia coli* in community, specialized outpatient clinic and hospital settings in Switzerland. *J Antimicrob Chemother* 2013;68:2249–54.
 93. Reyna-Flores F, Barrios H, Garza-Ramos U, *et al.* Molecular epidemiology of *Escherichia coli* O25b-ST131 isolates causing community-acquired UTIs in Mexico. *Diagn Microbiol Infect Dis* 2013;76:396–8.
 94. Mnif B, Harhour H, Jdidi J, *et al.* Molecular epidemiology of extended-spectrum beta-lactamase-producing *Escherichia coli* in Tunisia and characterization of their virulence factors and plasmid addition systems. *BMC Microbiol* 2013;13:147.
 95. Williamson DA, Freeman JT, Porter S, *et al.* Clinical and molecular correlates of virulence in *Escherichia coli* causing bloodstream infection following transrectal ultrasound-guided (TRUS) prostate biopsy. *J Antimicrob Chemother* 2013;68:2898–906.
 96. Kang CI, Cha MK, Kim SH, *et al.* Clinical and molecular epidemiology of community-onset bacteremia caused by extended-spectrum β -lactamase-producing *Escherichia coli* over a 6-year period. *J Korean Med Sci* 2013;28:998–1004.
 97. Kudinha T, Johnson JR, Andrew SD, *et al.* *Escherichia coli* sequence type 131 as a prominent cause of antibiotic resistance among urinary *Escherichia coli* isolates from reproductive-age women. *J Clin Microbiol* 2013;51:3270–6.

98. Hu YY, Cai JC, Zhou HW, *et al.* Molecular typing of CTX-M-producing *Escherichia coli* isolates from environmental water, swine feces, specimens from healthy humans, and human patients. *Appl Environ Microbiol* 2013;79:5988–96.
99. van der Donk C, van de Bovenkamp J, Bamelis H, *et al.* Prevalence and spread of multidrug-resistant *Escherichia coli* including ST131 in different patient populations in the Euroregion Meuse-Rhine. *Future Microbiol* 2013;8:1027–37.
100. Banerjee R, Strahilevitz J, Johnson JR, *et al.* Predictors and molecular epidemiology of community-onset extended-spectrum β -lactamase-producing *Escherichia coli* infection in a Midwestern community. *Infect Control Hosp Epidemiol* 2013;34:947–53.
101. Blanco J, Mora A, Mamani R, *et al.* Four main virotypes among extended-spectrum- β -lactamase-producing isolates of *Escherichia coli* O25b:H4-B2-ST131: bacterial, epidemiological, and clinical characteristics. *J Clin Microbiol* 2013;51:3358–67.
102. Colpan A, Johnston B, Porter S, *et al.* *Escherichia coli* sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. *Clin Infect Dis* 2013;57:1256–65.
103. Dahbi G, Mora A, López C, *et al.* Emergence of new variants of ST131 clonal group among extraintestinal pathogenic *Escherichia coli* producing extended-spectrum β -lactamases. *Int J Antimicrob Agents* 2013;42:347–51.
104. Horner C, Fawley W, Morris K, *et al.* *Escherichia coli* bacteraemia: 2 years of prospective regional surveillance (2010–12). *J Antimicrob Chemother* 2014;69:91–100.
105. Banerjee R, Johnston B, Lohse C, *et al.* The clonal distribution and diversity of extraintestinal *Escherichia coli* isolates vary according to patient characteristics. *Antimicrob Agents Chemother* 2013;57:5912–17.
106. Ha YE, Kang CI, Cha MK, *et al.* Epidemiology and clinical outcomes of bloodstream infections caused by extended-spectrum β -lactamase-producing *Escherichia coli* in patients with cancer. *Int J Antimicrob Agents* 2013;42:403–9.
107. Brolund A, Edquist PJ, Mäkitalo B, *et al.* Epidemiology of extended-spectrum β -lactamase-producing *Escherichia coli* in Sweden 2007–2011. *Clin Microbiol Infect* 2014;20:O344–52.
108. Aschbacher R, Giani T, Corda D, *et al.* Carbapenemase-producing Enterobacteriaceae during 2011–12 in the Bolzano area (Northern Italy): increasing diversity in a low-endemicity setting. *Diagn Microbiol Infect Dis* 2013;77:354–6.
109. Calhau V, Ribeiro G, Mendonça N, *et al.* Prevalent combination of virulence and plasmid-encoded resistance in ST 131 *Escherichia coli* strains. *Virulence* 2013;4:726–9.
110. Markovska R, Schneider I, Ivanova D, *et al.* Predominance of IncL/M and IncF plasmid types among CTX-M-ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in Bulgarian hospitals. *APMIS* 2014;122:608–15.
111. Ma L, Siu LK, Lin JC, *et al.* Updated molecular epidemiology of carbapenem-non-susceptible *Escherichia coli* in Taiwan: first identification of KPC-2 or NDM-1-producing *E. coli* in Taiwan. *BMC Infect Dis* 2013;13:599.
112. Brisse S, Diancourt L, Laouénan C, *et al.* Phylogenetic distribution of CTX-M- and non-extended-spectrum β -lactamase-producing *Escherichia coli* isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes. *J Clin Microbiol* 2012;50:2974–81.
113. Weissman SJ, Johnson JR, Tchesnokova V, *et al.* High-resolution two-locus clonal typing of extraintestinal pathogenic *Escherichia coli*. *Appl Environ Microbiol* 2012;78:1353–60.
114. Musumeci R, Rausa M, Giovannoni R, *et al.* Prevalence of plasmid-mediated quinolone resistance genes in uropathogenic *Escherichia coli* isolated in a teaching hospital of northern Italy. *Microb Drug Resist* 2012;18:33–41.
115. Oteo J, Cercenado E, Fernández-Romero S, *et al.* Extended-spectrum- β -lactamase-producing *Escherichia coli* as a cause of pediatric infections: report of a neonatal intensive care unit outbreak due to a CTX-M-14-producing strain. *Antimicrob Agents Chemother* 2012;56:54–8.
116. Gibreel TM, Dodgson AR, Cheesbrough J, *et al.* Population structure, virulence potential and antibiotic susceptibility of uropathogenic *Escherichia coli* from Northwest England. *J Antimicrob Chemother* 2012;67:346–56.
117. Chung HC, Lai CH, Lin JN, *et al.* Bacteremia caused by extended-spectrum- β -lactamase-producing *Escherichia coli* sequence type ST131 and non-ST131 clones: comparison of demographic data, clinical features, and mortality. *Antimicrob Agents Chemother* 2012;56:618–22.
118. Peirano G, van der Bij AK, Gregson DB, *et al.* Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β -lactamase-producing *Escherichia coli* causing bacteraemia in a centralized Canadian region. *J Clin Microbiol* 2012;50:294–9.
119. Tiruvury H, Johnson JR, Mariano N, *et al.* Identification of CTX-M β -lactamases among *Escherichia coli* from the community in New York City. *Diagn Microbiol Infect Dis* 2012;72:248–52.
120. Giuffrè M, Graziani C, Accogli M, *et al.* *Escherichia coli* of human and avian origin: detection of clonal groups associated with fluoroquinolone and multidrug resistance in Italy. *J Antimicrob Chemother* 2012;67:860–7.
121. Novais A, Rodrigues C, Branquinho R, *et al.* Spread of an OmpK36-modified ST15 *Klebsiella pneumoniae* variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. *Eur J Clin Microbiol Infect Dis* 2012;31:3057–63.
122. Matsumura Y, Nagao M, Iguchi M, *et al.* Molecular and clinical characterization of plasmid-mediated AmpC β -lactamase-producing *Escherichia coli* bacteraemia: a comparison with extended-spectrum β -lactamase-producing and non-resistant *E. coli* bacteraemia. *Clin Microbiol Infect* 2013;19:161–8.
123. Yokota S, Sato T, Okubo T, *et al.* Prevalence of fluoroquinolone-resistant *Escherichia coli* O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan. *Chemotherapy* 2012;58:52–9.
124. Johnson JR, Urban C, Weissman SJ, *et al.* AMERECUS Investigators. Molecular epidemiological analysis of *Escherichia coli* sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum- β -lactamase-producing *E. coli* from the United States, 2000 to 2009. *Antimicrob Agents Chemother* 2012;56:2364–70.
125. Williamson DA, Roberts SA, Paterson DL, *et al.* *Escherichia coli* bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. *Clin Infect Dis* 2012;54:1406–12.
126. Ho PL, Yeung MK, Lo WU, *et al.* Predominance of pHK01-like incompatibility group FII plasmids encoding CTX-M-14 among extended-spectrum beta-lactamase-producing *Escherichia coli* in Hong Kong, 1996–2008. *Diagn Microbiol Infect Dis* 2012;73:182–6.
127. Dimou V, Dhanji H, Pike R, *et al.* Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. *J Antimicrob Chemother* 2012;67:1660–5.
128. Burke L, Humphreys H, Fitzgerald-Hughes D. The revolving door between hospital and community: extended-spectrum beta-lactamase-producing *Escherichia coli* in Dublin. *J Hosp Infect* 2012;81:192–8.
129. Park SH, Byun JH, Choi SM, *et al.* Molecular epidemiology of extended-spectrum β -lactamase-producing *Escherichia coli* in the community and hospital in Korea: emergence of ST131 producing CTX-M-15. *BMC Infect Dis* 2012;12:149.
130. Reuland EA, Overdevest IT, Al Naiemi N, *et al.* High prevalence of ESBL-producing Enterobacteriaceae carriage in Dutch community patients with gastrointestinal complaints. *Clin Microbiol Infect* 2013;19:542–9.
131. Kuroda H, Yano H, Hirakata Y, *et al.* Molecular characteristics of extended-spectrum β -lactamase-producing *Escherichia coli* in Japan: emergence of CTX-M-15-producing *E. coli* ST131. *Diagn Microbiol Infect Dis* 2012;74:201–3.
132. Gibreel TM, Dodgson AR, Cheesbrough J, *et al.* High metabolic potential may contribute to the success of ST131 uropathogenic *Escherichia coli*. *J Clin Microbiol* 2012;50:3202–7.
133. Matsumura Y, Yamamoto M, Nagao M, *et al.* Emergence and spread of B2-ST131-O25b, B2-ST131-O16 and D-ST405 clonal groups among extended-spectrum- β -lactamase-producing *Escherichia coli* in Japan. *J Antimicrob Chemother* 2012;67:2612–20.
134. Österblad M, Kirveskari J, Hakanen AJ, *et al.* Carbapenemase-producing Enterobacteriaceae in Finland: the first years (2008–11). *J Antimicrob Chemother* 2012;67:2860–4.
135. Naseer U, Olsson-Liljequist BE, Woodford N, *et al.* Multi-locus variable number of tandem repeat analysis for rapid and accurate typing of virulent multidrug resistant *Escherichia coli* clones. *PLoS ONE* 2012;7:e41232.
136. Golding GR, Persaud N, Levett PN, *et al.* Characterization of *Escherichia coli* urinary tract infection isolates in remote northern Saskatchewan communities: the Northern Antibiotic Resistance Partnership. *Diagn Microbiol Infect Dis* 2012;74:242–7.
137. Hussain A, Ewers C, Nandanwar N, *et al.* Multiresistant uropathogenic *Escherichia coli* from a region in India where urinary tract infections are endemic: genotypic and phenotypic characteristics of sequence type 131 isolates of the CTX-M-15 extended-spectrum- β -lactamase-producing lineage. *Antimicrob Agents Chemother* 2012;56:6358–65.

138. van der Donk CF, van de Bovenkamp JH, De Brauwier EI, *et al.* Antimicrobial resistance and spread of multi drug resistant *Escherichia coli* isolates collected from nine urology services in the Euregion Meuse-Rhine. *PLoS ONE* 2012;7:e47707.
139. Mavroidi A, Miriagou V, Liakopoulos A, *et al.* Ciprofloxacin-resistant *Escherichia coli* in Central Greece: mechanisms of resistance and molecular identification. *BMC Infect Dis* 2012;12:371.
140. Peirano G, Asensi MD, Pitondo-Silva A, *et al.* Molecular characteristics of extended-spectrum β -lactamase-producing *Escherichia coli* from Rio de Janeiro, Brazil. *Clin Microbiol Infect* 2011;17:1039–43.
141. Peirano G, van Greune CH, Pitout JD. Characteristics of infections caused by extended-spectrum β -lactamase-producing *Escherichia coli* from community hospitals in South Africa. *Diagn Microbiol Infect Dis* 2011;69:449–53.
142. Overdevest I, Willemsen I, Rijnsburger M, *et al.* Extended-spectrum β -lactamase genes of *Escherichia coli* in chicken meat and humans, The Netherlands. *Emerg Infect Dis* 2011;17:1216–22.
143. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, *et al.* National ESBL surveillance group. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. *Clin Microbiol Infect* 2011;17:873–80.
144. Courpon-Claudinon A, Lefort A, Panhard X, *et al.* Bacteraemia caused by third-generation cephalosporin-resistant *Escherichia coli* in France: prevalence, molecular epidemiology and clinical features. *Clin Microbiol Infect* 2011;17:557–65.
145. Rodriguez-Villalobos H, Bogaerts P, Berhin C, *et al.* Trends in production of extended-spectrum beta-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. *J Antimicrob Chemother* 2011;66:37–47.
146. Mora A, Blanco M, López C, *et al.* Emergence of clonal groups O1: HNM-D-ST59, O15:H1-D-ST393, O20:H34/HNM-D-ST354, O25b: H4-B2-ST131 and ONT:H21,42-B1-ST101 among CTX-M-14-producing *Escherichia coli* clinical isolates in Galicia, northwest Spain. *Int J Antimicrob Agents* 2011;37:16–21.
147. Coelho A, Mora A, Mamani R, *et al.* Spread of *Escherichia coli* O25b:H4-B2-ST131 producing CTX-M-15 and SHV-12 with high virulence gene content in Barcelona (Spain). *J Antimicrob Chemother* 2011;66:517–26.
148. Xu L, Shabir S, Bodah T, *et al.* Regional survey of CTX-M-type extended-spectrum β -lactamases among Enterobacteriaceae reveals marked heterogeneity in the distribution of the ST131 clone. *J Antimicrob Chemother* 2011;66:505–11.
149. Ruiz SJ, Montealegre MC, Ruiz-Garbajosa P, *et al.* First characterization of CTX-M-15-producing *Escherichia coli* ST131 and ST405 clones causing community-onset infections in South America. *J Clin Microbiol* 2011;49:1993–6.
150. Simner PJ, Zhanel GG, Pitout J, *et al.* Prevalence and characterization of extended-spectrum β -lactamase- and AmpC β -lactamase-producing *Escherichia coli*: results of the CANWARD 2007–2009 study. *Diagn Microbiol Infect Dis* 2011;69:326–34.
151. Dhanji H, Patel R, Wall R, *et al.* Variation in the genetic environments of bla(CTX-M-15) in *Escherichia coli* from the faeces of travellers returning to the United Kingdom. *J Antimicrob Chemother* 2011;66:1005–12.
152. Kim J, Bae IK, Jeong SH, *et al.* Characterization of IncF plasmids carrying the blaCTX-M-14 gene in clinical isolates of *Escherichia coli* from Korea. *J Antimicrob Chemother* 2011;66:1263–8.
153. van der Bij AK, Peirano G, Goessens WHF, *et al.* Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing *Escherichia coli* causing bacteremia in the Rotterdam Area, Netherlands. *Antimicrob Agents Chemother* 2011;55:3576–8.
154. Titelman E, Karlsson IM, Ge Y, *et al.* In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing *Escherichia coli* and *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis* 2011;70:137–41.
155. Cao X, Cavaco LM, Lv Y, *et al.* Molecular characterization and antimicrobial susceptibility testing of *Escherichia coli* isolates from patients with urinary tract infections in 20 Chinese hospitals. *J Clin Microbiol* 2011;49:2496–501.
156. Mshana SE, Imirzalioglu C, Hain T, *et al.* Multiple ST clonal complexes, with a predominance of ST131, of *Escherichia coli* harbouring blaCTX-M-15 in a tertiary hospital in Tanzania. *Clin Microbiol Infect* 2011;17:1279–82.
157. Blanco J, Mora A, Mamani R, *et al.* National survey of *Escherichia coli* causing extraintestinal infections reveals the spread of drug-resistant clonal groups O25b:H4-B2-ST131, O15:H1-D-ST393 and CGA-D-ST69 with high virulence gene content in Spain. *J Antimicrob Chemother* 2011;66:2011–21.
158. Shin J, Kim DH, Ko KS. Comparison of CTX-M-14- and CTX-M-15-producing *Escherichia coli* and *Klebsiella pneumoniae* isolates from patients with bacteremia. *J Infect* 2011;63:39–47.
159. Croxall G, Hale J, Weston V, *et al.* Molecular epidemiology of extraintestinal pathogenic *Escherichia coli* isolates from a regional cohort of elderly patients highlights the prevalence of ST131 strains with increased antimicrobial resistance in both community and hospital care settings. *J Antimicrob Chemother* 2011;66:2501–8.
160. Simner PJ, Hoban DJ, Lagacé-Wiens PRS, *et al.* Fluoroquinolone resistance in *Escherichia coli* isolated from patients attending Canadian hospitals is associated with the ST131 clone. *Diagn Microbiol Infect Dis* 2011;71:323–4.
161. Titelman E, Iversen A, Kahlmeter G, *et al.* Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing *Escherichia coli* and *Klebsiella pneumoniae*. *APMIS* 2011;119:853–63.
162. Molina-López J, Aparicio-Ozores G, Ribas-Aparicio RM, *et al.* Drug resistance, serotypes, and phylogenetic groups among uropathogenic *Escherichia coli* including O25-ST131 in Mexico City. *J Infect Dev Ctries* 2011;5:840–9. <http://www.ncbi.nlm.nih.gov/pubmed/22169782> (accessed 20 May 2015).
163. Sidjabat HE, Derrington P, Nimmo GR, *et al.* *Escherichia coli* ST131 producing CTX-M-15 in Australia. *J Antimicrob Chemother* 2010;65:1301–3.
164. Tian GB, Garcia J, Adams-Haduch JM, *et al.* CTX-M as the predominant extended-spectrum beta-lactamases among Enterobacteriaceae in Manila, Philippines. *J Antimicrob Chemother* 2010;65:584–6.
165. Platell JL, Cobbold RN, Johnson JR, *et al.* Clonal group distribution of fluoroquinolone-resistant *Escherichia coli* among humans and companion animals in Australia. *J Antimicrob Chemother* 2010;65:1936–8.
166. Naseer U, Haldorsen B, Simonsen GS, *et al.* Sporadic occurrence of CMY-2-producing multidrug-resistant *Escherichia coli* of ST-complexes 38 and 448, and ST131 in Norway. *Clin Microbiol Infect* 2010;16:171–8.
167. Johnson JR, Johnston B, Clabots C, *et al.* *Escherichia coli* sequence type ST131 as an emerging fluoroquinolone-resistant uropathogen among renal transplant recipients. *Antimicrob Agents Chemother* 2010;54:546–50.
168. Lee MY, Choi HJ, Choi JY, *et al.* Dissemination of ST131 and ST393 community-onset, ciprofloxacin-resistant *Escherichia coli* clones causing urinary tract infections in Korea. *J Infect* 2010;60:146–53.
169. Peirano G, Richardson D, Nigrin J, *et al.* High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing *Escherichia coli* isolates from Canada. *Antimicrob Agents Chemother* 2010;54:1327–30.
170. Severin JA, Mertaniasih NM, Kuntaman K, *et al.* Molecular characterization of extended-spectrum beta-lactamases in clinical *Escherichia coli* and *Klebsiella pneumoniae* isolates from Surabaya, Indonesia. *J Antimicrob Chemother* 2010;65:465–9.
171. Cerquetti M, Giuffrè M, García-Fernández A, *et al.* Ciprofloxacin-resistant, CTX-M-15-producing *Escherichia coli* ST131 clone in extraintestinal infections in Italy. *Clin Microbiol Infect* 2010;16:1555–8.
172. Peirano G, Costello M, Pitout JDD. Molecular characteristics of extended-spectrum beta-lactamase-producing *Escherichia coli* from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. *Int J Antimicrob Agents* 2010;36:19–23.
173. Smet A, Martel A, Persoons D, *et al.* Characterization of extended-spectrum beta-lactamases produced by *Escherichia coli* isolated from hospitalized and nonhospitalized patients: emergence of CTX-M-15-producing strains causing urinary tract infections. *Microb Drug Resist* 2010;16:129–34.
174. Dahmen S, Bettaieb D, Mansour W, *et al.* Characterization and molecular epidemiology of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in a Tunisian University Hospital. *Microb Drug Resist* 2010;16:163–70.
175. Oteo J, Cercenado E, Cuevas O, *et al.* AmpC beta-lactamases in *Escherichia coli*: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. *Diagn Microbiol Infect Dis* 2010;67:270–6.
176. Díaz MA, Hernández-Bello JR, Rodríguez-Baño J, *et al.* Spanish Group for Nosocomial Infections (GEIH). Diversity of *Escherichia coli* strains producing extended-spectrum β -lactamases in Spain: second nationwide study. *J Clin Microbiol* 2010;48:2840–5.
177. Bert F, Johnson JR, Ouattara B, *et al.* Genetic diversity and virulence profiles of *Escherichia coli* isolates causing spontaneous

- bacterial peritonitis and bacteremia in patients with cirrhosis. *J Clin Microbiol* 2010;48:2709–14.
178. Johnson JR, Johnston B, Clabots C, *et al*. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. *Clin Infect Dis* 2010;51:286–94.
 179. Vidal-Navarro L, Pfeiffer C, Bouziges N, *et al*. Faecal carriage of multidrug-resistant Gram-negative bacilli during a non-outbreak situation in a French university hospital. *J Antimicrob Chemother* 2010;65:2455–8.
 180. Brölund A, Hæggman S, Edquist PJ, *et al*. The DiversiLab system versus pulsed-field gel electrophoresis: characterisation of extended spectrum β -lactamase producing Escherichia coli and Klebsiella pneumoniae. *J Microbiol Methods* 2010;83:224–30.
 181. Jouini A, Ben Slama K, Vinué L, *et al*. Detection of unrelated Escherichia coli strains harboring genes of CTX-M-15, OXA-1, and AAC(6)-Ib-cr enzymes in a Tunisian hospital and characterization of their integrons and virulence factors. *J Chemother* 2010;22:318–23.
 182. Pitout JDD, Campbell L, Church DL, *et al*. Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. *Antimicrob Agents Chemother* 2009;53:2539–43.
 183. Morris D, Boyle F, Buckley V, *et al*. CTX-M enzymes are the predominant extended-spectrum beta-lactamases produced by Enterobacteriaceae in Ireland. *J Antimicrob Chemother* 2009;64:864–6.
 184. Hrabák J, Empel J, Bergerová T, *et al*. International clones of Klebsiella pneumoniae and Escherichia coli with extended-spectrum β -lactamases in a Czech Hospital. *J Clin Microbiol* 2009;47:3353–7.
 185. Suzuki S, Shibata N, Yamane K, *et al*. Change in the prevalence of extended-spectrum-beta-lactamase-producing Escherichia coli in Japan by clonal spread. *J Antimicrob Chemother* 2009;63:72–9.
 186. Literacka E, Bedenic B, Baraniak A, *et al*. blaCTX-M genes in Escherichia coli strains from Croatian Hospitals are located in new (blaCTX-M-3a) and widely spread (blaCTX-M-3a and blaCTX-M-15) genetic structures. *Antimicrob Agents Chemother* 2009;53:1630–5.
 187. Pitout JDD, Campbell L, Church DL, *et al*. Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. *J Clin Microbiol* 2009;47:1212–15.
 188. Arpin C, Quentin C, Grobost F, *et al*. Nationwide survey of extended-spectrum (beta)-lactamase-producing Enterobacteriaceae in the French community setting. *J Antimicrob Chemother* 2009;63:1205–14.
 189. Blanco M, Alonso MP, Nicolas-Chanoine MH, *et al*. Molecular epidemiology of Escherichia coli producing extended-spectrum (beta)-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. *J Antimicrob Chemother* 2009;63:1135–41.
 190. Pitout JDD, Gregson DB, Campbell L, *et al*. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to 2007: emergence of clone ST131 as a cause of community-acquired infections. *Antimicrob Agents Chemother* 2009;53:2846–51.
 191. Johnson JR, Menard M, Johnston B, *et al*. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. *Antimicrob Agents Chemother* 2009;53:2733–9.
 192. Oteo J, Diestra K, Juan C, *et al*. Extended-spectrum beta-lactamase-producing Escherichia coli in Spain belong to a large variety of multilocus sequence typing types, including ST10 complex/A, ST23 complex/A and ST131/B2. *Int J Antimicrob Agents* 2009;34:173–6.
 193. Clermont O, Dhanji H, Upton M, *et al*. Rapid detection of the O25b-ST131 clone of Escherichia coli encompassing the CTX-M-15-producing strains. *J Antimicrob Chemother* 2009;64:274–7.
 194. Naseer U, Haldorsen B, Tofteland S, *et al*. Molecular characterization of CTX-M-15-producing clinical isolates of Escherichia coli reveals the spread of multidrug-resistant ST131 (O25:H4) and ST964 (O102:H6) strains in Norway. *APMIS* 2009;117:526–36.
 195. Oteo J, Orden B, Bautista V, *et al*. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. *J Antimicrob Chemother* 2009;64:712–17.
 196. Sidjabat HE, Paterson DL, Adams-Haduch JM, *et al*. Molecular epidemiology of CTX-M-producing Escherichia coli isolates at a tertiary medical center in western Pennsylvania. *Antimicrob Agents Chemother* 2009;53:4733–9.
 197. Lau SH, Reddy S, Cheesbrough J, *et al*. Major uropathogenic Escherichia coli strain isolated in the northwest of England identified by multilocus sequence typing. *J Clin Microbiol* 2008;46:1076–80.
 198. Yumuk Z, Afacan G, Nicolas-Chanoine MH, *et al*. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. *J Antimicrob Chemother* 2008;62:284–8.
 199. Cagnacci S, Gualco L, Debbia E, *et al*. European emergence of ciprofloxacin-resistant Escherichia coli clonal groups O25:H4-ST131 and O15:K52:H1 causing community-acquired uncomplicated cystitis. *J Clin Microbiol* 2008;46:2605–12.
 200. Jones GL, Warren RE, Skidmore SJ, *et al*. Prevalence and distribution of plasmid-mediated quinolone resistance genes in clinical isolates of Escherichia coli lacking extended-spectrum beta-lactamases. *J Antimicrob Chemother* 2008;62:1245–51.
 201. Fam NS, Defasque S, Bert F, *et al*. Faecal carriage of extended-spectrum β -lactamase (ESBL)-producing enterobacteria in liver disease patients from two hospitals in Egypt and France: a comparative epidemiological study. *Epidemiol Infect* 2015;143:1247–55.
 202. Liss MA, Johnson JR, Porter SB. Clinical and microbiological determinants of infection after transrectal prostate biopsy. *Clin Infect Dis* 2015;60:979–87.
 203. Valverde A, Turrientes MC, Norman F, *et al*. CTX-M-15-non-ST131 Escherichia coli isolates are mainly responsible of faecal carriage with ESBL-producing Enterobacteriaceae in travellers, immigrants and those visiting friends and relatives. *Clin Microbiol Infect* 2015;21:252.e1–4.
 204. Stewardson AJ, Renzi G, Maury N, *et al*. Extended-spectrum β -lactamase-producing Enterobacteriaceae in hospital food: a risk assessment. *Infect Control Hosp Epidemiol* 2014;35:375–83.
 205. Yaita K, Aoki K, Suzuki T, *et al*. Epidemiology of extended-spectrum β -lactamase producing Escherichia coli in the stools of returning Japanese travelers, and the risk factors for colonization. *PLoS ONE* 2014;9:e98000.
 206. Lupindu AM, Olsen JE, Ngowi HA, *et al*. Occurrence and characterization of Shiga toxin-producing Escherichia coli O157:H7 and other non-sorbitol-fermenting E. coli in cattle and humans in urban areas of Morogoro, Tanzania. *Vector Borne Zoonotic Dis* 2014;14:503–10.
 207. Vervoort J, Gazin M, Kazma M, *et al*. High rates of intestinal colonisation with fluoroquinolone-resistant ESBL-harbouring Enterobacteriaceae in hospitalised patients with antibiotic-associated diarrhoea. *Eur J Clin Microbiol Infect Dis* 2014;33:2215–21.
 208. Han JH, Johnston B, Nachamkin I, *et al*. Clinical and molecular epidemiology of Escherichia coli sequence type 131 among hospitalized patients colonized intestinally with fluoroquinolone-resistant E. coli. *Antimicrob Agents Chemother* 2014;58:7003–6.
 209. Vasoo S, Madigan T, Cunningham SA, *et al*. Prevalence of rectal colonization with multidrug-resistant Enterobacteriaceae among international patients hospitalized at Mayo Clinic, Rochester, Minnesota. *Infect Control Hosp Epidemiol* 2014;35:182–6.
 210. March A, Aschbacher R, Pagani E, *et al*. Changes in colonization of residents and staff of a long-term care facility and an adjacent acute-care hospital geriatric unit by multidrug-resistant bacteria over a four-year period. *Scand J Infect Dis* 2014;46:114–22.
 211. Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, *et al*. 10-Fold increase (2006–11) in the rate of healthy subjects with extended-spectrum β -lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. *J Antimicrob Chemother* 2013;68:562–8.
 212. Izdebski R, Baraniak A, Fiett J, *et al*. MOSAR WP2 and WP5 Study Groups. Clonal structure, extended-spectrum β -lactamases, and acquired AmpC-type cephalosporinases of Escherichia coli populations colonizing patients in rehabilitation centers in four countries. *Antimicrob Agents Chemother* 2013;57:309–16.
 213. Liss MA, Peterson EM, Johnston B, *et al*. Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. *Urology* 2013;81:548–55.
 214. Birgy A, Mariani-Kurkdjian P, Bidet P, *et al*. Characterization of extended-spectrum-beta-lactamase-producing Escherichia coli strains involved in maternal-fetal colonization: prevalence of E. coli ST131. *J Clin Microbiol* 2013;51:1727–32.
 215. Nüesch-Inderbinen MT, Abgottspon H, Zurfluh K, *et al*. Cross-sectional study on fecal carriage of Enterobacteriaceae with

- resistance to extended-spectrum cephalosporins in primary care patients. *Microb Drug Resist* 2013;19:362–9.
216. Arvand M, Moser V, Pfeifer Y. Prevalence of extended-spectrum- β -lactamase-producing *Escherichia coli* and spread of the epidemic clonal lineage ST131 in nursing homes in Hesse, Germany. *J Antimicrob Chemother* 2013;68:2686–8.
 217. Roy S, Krishnan R, Mukherjee S, *et al.* Prevalence of ST131 virulence-associated strains among CTX-M-producing *Escherichia coli* in the gut of hospitalized neonates in India. *Diagn Microbiol Infect Dis* 2013;77:158–9.
 218. Severin JA, Lestari ES, Kloezen W, *et al.* Faecal carriage of extended-spectrum β -lactamase-producing Enterobacteriaceae among humans in Java, Indonesia, in 2001–2002. *Trop Med Int Health* 2012;17:455–61.
 219. Dolejska M, Brhelova E, Dobiasova H, *et al.* Dissemination of IncFII(K)-type plasmids in multiresistant CTX-M-15-producing Enterobacteriaceae isolates from children in hospital paediatric oncology wards. *Int J Antimicrob Agents* 2012;40:510–15.
 220. Li B, Sun JY, Liu QZ, *et al.* High prevalence of CTX-M β -lactamases in faecal *Escherichia coli* strains from healthy humans in Fuzhou, China. *Scand J Infect Dis* 2011;43:170–4.
 221. Peirano G, Laupland KB, Gregson DB, *et al.* Colonization of returning travelers with CTX-M-producing *Escherichia coli*. *J Travel Med* 2011;18:299–303.
 222. Leflon-Guibout V, Blanco J, Amaqdouf K, *et al.* Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal *Escherichia coli* isolates from healthy subjects living in the area of Paris, France. *J Clin Microbiol* 2008;46:3900–5.
 223. Diago-Navarro E, Chen L, Passet V, *et al.* Carbapenem-resistant *Klebsiella pneumoniae* exhibit variability in capsular polysaccharide and capsule associated virulence traits. *J Infect Dis* 2014;210:803–13.
 224. van Duin D, Perez F, Rudin SD, *et al.* Surveillance of carbapenem-resistant *Klebsiella pneumoniae*: tracking molecular epidemiology and outcomes through a regional network. *Antimicrob Agents Chemother* 2014;58:4035–41.
 225. Mezzatesta ML, Caio C, Gona F, *et al.* Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs. *Int J Antimicrob Agents* 2014;44:112–16.
 226. Ageevets VA, Partina IV, Lisitsyna ES, *et al.* Emergence of carbapenemase-producing Gram-negative bacteria in Saint Petersburg, Russia. *Int J Antimicrob Agents* 2014;44:152–5.
 227. Tijet N, Sheth PM, Lastovetska O, *et al.* Molecular characterization of *Klebsiella pneumoniae* carbapenemase (KPC)-producing Enterobacteriaceae in Ontario, Canada, 2008–2011. *PLoS ONE* 2014;9:e116421.
 228. Hrabák J, Papagiannitsis CC, Študentová V, *et al.* Carbapenemase-producing *Klebsiella pneumoniae* in the Czech Republic in 2011. *Euro Surveill* 2013;18:20626. <http://www.ncbi.nlm.nih.gov/pubmed/24229789> (accessed 20 May 2015).
 229. Lascols C, Peirano G, Hackel M, *et al.* Surveillance and molecular epidemiology of *Klebsiella pneumoniae* isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. *Antimicrob Agents Chemother* 2013;57:130–6.
 230. Castanheira M, Farrell SE, Wanger A, *et al.* Rapid expansion of KPC-2-producing *Klebsiella pneumoniae* isolates in two Texas hospitals due to clonal spread of ST258 and ST307 lineages. *Microb Drug Resist* 2013;19:295–7.
 231. Rodríguez-Zulueta P, Silva-Sánchez J, Barrios H, *et al.* First outbreak of KPC-3-producing *Klebsiella pneumoniae* (ST258) clinical isolates in a Mexican Medical Center. *Antimicrob Agents Chemother* 2013;57:4086–8.
 232. Di Carlo P, Gulotta G, Casuccio A, *et al.* KPC—3 *Klebsiella pneumoniae* ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. *BMC Anesthesiol* 2013;13:13.
 233. Jain R, Walk ST, Aronoff DM, *et al.* Emergence of Carbapenemase-producing *Klebsiella pneumoniae* of Sequence type 258 in Michigan, USA. *Infect Dis Rep* 2013;5:e5.
 234. Cejas D, Fernandez Canigia L, Nastro M, *et al.* Hyperendemic clone of KPC producing *Klebsiella pneumoniae* ST 258 in Buenos Aires hospitals. *Infect Genet Evol* 2012;12:499–501.
 235. Warburg G, Hidalgo-Grass C, Partridge SR, *et al.* A carbapenem-resistant *Klebsiella pneumoniae* epidemic clone in Jerusalem: sequence type 512 carrying a plasmid encoding aac (6')-Ib. *J Antimicrob Chemother* 2012;67:898–901.
 236. Richter SN, Frasson I, Franchin E, *et al.* KPC-mediated resistance in *Klebsiella pneumoniae* in two hospitals in Padua, Italy, June 2009–December 2011: massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units. *Gut Pathog* 2012;4:7.
 237. Adler A, Paikin S, Sterlin Y, *et al.* A swordless knight: epidemiology and molecular characteristics of the blaKPC-negative sequence type 258 *Klebsiella pneumoniae* clone. *J Clin Microbiol* 2012;50:3180–5.
 238. Mammina C, Bonura C, Di Bernardo F, *et al.* Ongoing spread of colistin-resistant *Klebsiella pneumoniae* in different wards of an acute general hospital, Italy, June to December 2011. *Euro Surveill* 2012;17:pii: 20248. <http://www.ncbi.nlm.nih.gov/pubmed/22913977> (accessed 20 May 2015).
 239. Mataseje LF, Boyd DA, Willey BM, *et al.* Plasmid comparison and molecular analysis of *Klebsiella pneumoniae* harbouring bla(KPC) from New York City and Toronto. *J Antimicrob Chemother* 2011;66:1273–7.
 240. Giakkoupi P, Papagiannitsis CC, Miriagou V, *et al.* An update of the evolving epidemic of blaKPC-2-carrying *Klebsiella pneumoniae* in Greece (2009–10). *J Antimicrob Chemother* 2011;66:1510–13.
 241. Andrade LN, Curiao T, Ferreira JC, *et al.* Dissemination of blaKPC-2 by the spread of *Klebsiella pneumoniae* clonal complex 258 clones (ST258, ST11, ST437) and plasmids (IncFII, IncN, IncL/M) among Enterobacteriaceae species in Brazil. *Antimicrob Agents Chemother* 2011;55:3579–83.
 242. Gomez SA, Pasteran FG, Faccone D, *et al.* Clonal dissemination of *Klebsiella pneumoniae* ST258 harbouring KPC-2 in Argentina. *Clin Microbiol Infect* 2011;17:1520–4.
 243. Baraniak A, Grabowska A, Izdebski R, *et al.* Molecular characteristics of KPC-producing Enterobacteriaceae at the early stage of their dissemination in Poland, 2008–2009. *Antimicrob Agents Chemother* 2011;55:5493–9.
 244. Cuzon G, Naas T, Truong H, *et al.* Worldwide diversity of *Klebsiella pneumoniae* that produce beta-lactamase blaKPC-2 gene. *Emerg Infect Dis* 2010;16:1349–56.
 245. Endimiani A, Depasquale JM, Forero S, *et al.* Emergence of blaKPC-containing *Klebsiella pneumoniae* in a long-term acute care hospital: a new challenge to our healthcare system. *J Antimicrob Chemother* 2009;64:1102–10.
 246. Paterson GK, Harrison EM, Murray GGR, *et al.* Capturing the cloud of diversity reveals complexity and heterogeneity of MRSA carriage, infection and transmission. *Nat Commun* 2015;6:6560.